Personalis (NASDAQ:PSNL) Receives Average Rating of “Buy” from Analysts

Shares of Personalis (NASDAQ:PSNL) have earned a consensus recommendation of “Buy” from the eight analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $25.20.

PSNL has been the subject of several research analyst reports. Needham & Company LLC initiated coverage on Personalis in a report on Monday, August 17th. They set a “buy” rating and a $25.00 price target for the company. Morgan Stanley lifted their target price on Personalis from $14.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. BidaskClub cut Personalis from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 26th. Oppenheimer assumed coverage on Personalis in a report on Wednesday, June 24th. They issued a “buy” rating and a $24.00 target price for the company. Finally, ValuEngine lowered Personalis from a “buy” rating to a “hold” rating in a research note on Tuesday, August 4th.

In other Personalis news, major shareholder Lightspeed Venture Partners Se bought 1,315,789 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average cost of $19.00 per share, for a total transaction of $24,999,991.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Aaron Tachibana sold 2,899 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $22.99, for a total value of $66,648.01. Following the transaction, the chief financial officer now owns 181,071 shares in the company, valued at $4,162,822.29. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,042,032 shares of company stock valued at $19,871,216. Corporate insiders own 8.20% of the company’s stock.

A number of institutional investors have recently bought and sold shares of PSNL. JPMorgan Chase & Co. grew its stake in Personalis by 51.0% during the 1st quarter. JPMorgan Chase & Co. now owns 1,570,978 shares of the company’s stock valued at $12,678,000 after purchasing an additional 530,936 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Personalis by 46.1% in the first quarter. BlackRock Inc. now owns 1,512,804 shares of the company’s stock worth $12,208,000 after buying an additional 477,674 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its stake in shares of Personalis by 113.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 523,750 shares of the company’s stock worth $6,794,000 after buying an additional 278,443 shares during the last quarter. Gabelli Funds LLC boosted its stake in shares of Personalis by 65.9% in the first quarter. Gabelli Funds LLC now owns 307,000 shares of the company’s stock worth $2,477,000 after buying an additional 122,000 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Personalis by 85.6% in the first quarter. State Street Corp now owns 257,475 shares of the company’s stock worth $2,078,000 after buying an additional 118,714 shares during the last quarter. Institutional investors and hedge funds own 61.62% of the company’s stock.

Shares of NASDAQ PSNL traded down $0.55 during trading on Monday, hitting $23.57. The company had a trading volume of 646,141 shares, compared to its average volume of 425,251. The stock has a 50 day simple moving average of $21.24 and a 200 day simple moving average of $13.64. Personalis has a 12 month low of $4.27 and a 12 month high of $24.87. The firm has a market capitalization of $751.53 million, a P/E ratio of -23.34 and a beta of 1.91.

Personalis (NASDAQ:PSNL) last issued its earnings results on Thursday, August 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.05. The company had revenue of $19.50 million for the quarter, compared to the consensus estimate of $17.05 million. Personalis had a negative return on equity of 31.11% and a negative net margin of 43.16%. Equities analysts anticipate that Personalis will post -1.15 EPS for the current fiscal year.

Personalis Company Profile

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT platform, a clinical-grade, next generation sequencing and analysis platform that enables the development of ImmunoID NeXT tumor biopsy and liquid biopsy, as well as provides analysis of tumor and immune microenvironment from a single limited tissue sample, tumor molecular profiling for cancer patients, and anticipates future cancer biomarkers.

Featured Article: What are the economic characteristics of a bear market?

Analyst Recommendations for Personalis (NASDAQ:PSNL)

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.